Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Adenoviral p53 Human Gene Combined With Chemotherapy in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

NCT02435186 is registered in ClinicalTrials.gov with Shenzhen SiBiono GeneTech Co.,Ltd as lead sponsor.

NCT NCT02435186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02435186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Adenoviral p53 Human Gene Combined With Chemotherapy in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Lead sponsor
Shenzhen SiBiono GeneTech Co.,Ltd
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2015
Completion date
August 31, 2018
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian epithelial cancer, primary peritoneal cancer